Updated:
Voyager Therapeutics
Voyager Therapeutics was founded in 2013 to translate adeno-associated virus research from the University of Massachusetts into gene therapies for...
Voyager Therapeutics
Voyager Therapeutics was founded in 2013 to translate adeno-associated virus research from the University of Massachusetts into gene therapies for neurological diseases. Early backers included Third Rock Ventures, which seeded the company alongside its launch. The firm went public in 2015, listing on Nasdaq under the ticker VYGR. Voyager operates a hybrid discovery-and-licensing model: an internal pipeline targeting diseases such as Alzheimer's and Parkinson's, complemented by a technology platform that designs novel AAV capsids capable of crossing the blood-brain barrier. This platform is the economic engine. The firm has consistently raised R&D capital by selling access to its capsid libraries — Neurocrine Biosciences signed a broad gene therapy collaboration in 2019, and in 2024, Novartis paid $100M upfront under a new agreement (per the firm, January 2024). Earlier partners included Pfizer and Sanofi Genzyme, though some programs were later restructured or returned. As of mid-2025, Voyager reported a growing cash position above $500M, largely from partnership milestones, which the firm has publicly stated it expects to fund operations into 2028 (per the firm, 2024). The company operates from a single headquarters in Lexington, Massachusetts and employed roughly 100 professionals at its last public disclosure. In January 2024, the firm announced a strategic collaboration with Novartis, securing $100M upfront along with equity investment for AAV capsid-based gene therapies targeting Huntington's disease and spinal muscular atrophy. Voyager's structural distinction comes from behaving less like an early-stage pipeline biotech and more like a fee-for-platform licensing business. It does not build toward large-scale commercial manufacturing, and it has returned rights on multiple internal programs to partners. This keeps the burn rate lower than peers, though it also makes the firm's fate intertwined with partners advancing their own clinical programs using Voyager's engineered capsids.
General information
Firm type
Asset Manager
Year founded
2013
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Lexington
Corporate office
Lexington, MA, United States
Principals
Alfred Sandrock
Chief Executive Officer
Todd Carter
Chief Scientific Officer
Sector focus
Frequently asked questions
How does Voyager Therapeutics fund its R&D?
Voyager primarily secures capital by entering licensing agreements and R&D collaborations for its blood-brain barrier-crossing AAV capsid technology. Partners like Neurocrine Biosciences and Novartis pay upfront fees, milestones, and development costs in exchange for access to the platform for specific disease targets. As of 2024, these deals have generated over $1.5B in committed partner funding since inception.
What is Voyager's core technological differentiator?
Voyager designs next-generation AAV capsids through its TRACER platform. TRACER uses selection-driven evolution to engineer novel capsids that can cross the blood-brain barrier, a historical hurdle for gene therapy, with higher efficiency and specificity for central nervous system cell types. This platform is the primary asset Voyager monetizes through partnerships.
Does Voyager Therapeutics operate its own gene therapy manufacturing?
No. Voyager does not build or operate large-scale commercial manufacturing facilities. The firm's strategy is to discover and engineer novel capsid variants, advance select internal programs to early clinical proof-of-concept, and then collaborate with or license to larger partners who handle late-stage development, manufacturing, and commercialization.
How is Voyager's pipeline split between internal programs and partnered programs?
Voyager maintains a small internal pipeline historically focused on Alzheimer's disease, Parkinson's disease, and other CNS disorders. The bulk of its programs are partnered and funded by external collaborators. For example, Neurocrine Biosciences has led development for programs in Friedreich's ataxia, while Novartis now leads work on Huntington's disease and spinal muscular atrophy using Voyager's capsids.
Who makes investment decisions at Voyager Therapeutics?
Voyager Therapeutics is a public company governed by a board of directors, currently chaired by Alfred Sandrock, who also serves as CEO. Strategic decisions — partner selection, capital allocation between platform and internal pipeline, and clinical development paths — are made by the executive team led by Sandrock and Chief Scientific Officer Todd Carter.
Has Voyager had any notable partner program restructurings?
Yes. Previous capsids licensed to Pfizer and Sanofi Genzyme have had rights revert to Voyager following portfolio restructurings or decisions by the partners to deprioritize certain disease targets. Voyager has publicly stated it can relicense these capsids to new collaborators under follow-on deals.
What is Voyager's known posture on additional pipeline in-licensing?
Voyager's disclosed strategy is to develop its own capsid-engineering platform, not to in-license external assets. The firm adds pipeline programs by applying novel capsids from TRACER to new disease targets internally, or lets partners pick specific targets to fund using Voyager's library under a paid license.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: